Women patients with small‐cell lung cancer using immunotherapy in a real‐world cohort achieved long‐term survival

Yuling He,Lingdong Kong,Xumeng Ji,Minglei Zhuo,Tongtong An,Bo Jia,Yujia Chi,Jingjing Wang,Jun Zhao,Jianjie Li,Xue Yang,Hanxiao Chen,Xiaoyu Zhai,Yidi Tai,Lu Ding,Ziping Wang,Yuyan Wang

DOI: https://doi.org/10.1111/1759-7714.15393

IF: 3.223

2024-06-25

Thoracic Cancer

Abstract:Our study suggested that female extensive‐stage small‐cell lung cancer patients treated with immunotherapy tended to achieve a relatively longer survival. The incidence of adverse events (grade ≥3) was higher in women patients receiving immune checkpoint inhibitors (ICIs), which requires monitoring more closely. Background Usage of immune checkpoint inhibitors (ICIs) has prolonged the overall survival (OS) of patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). In clinical trials, males accounted for a large proportion, leading to the uncertainty of its efficacy in female patients. We therefore conducted this study to explore the efficacy and safety of using ICIs in female patients with ES‐SCLC. Methods We retrospectively enrolled female SCLC patients and subdivided them into two groups. Group A (n = 40) was defined as ES‐SCLC patients who received first‐line standard chemotherapy with or without ICIs. Group B (n = 47) included relapsed SCLC patients who were administered with second‐line therapies. Kaplan–Meier methodology was used to calculate survival analysis. Chi‐squared tests were used to analyze the incidence of adverse events (AEs). Results Median progression‐free survival (PFS) and median OS favored the ICI‐contained cohorts (Group A PFS: 8.3 vs. 6.1 months; OS: not reached vs. 11.3 months; Group B PFS: 15.1 vs. 3.3 months; OS: 35.3 vs. 8.3 months), especially in those patients who received second‐line immunotherapies. Patients who received immunotherapy had a slightly higher incidence rate of grade ≥3 AEs (Group A: 71.4% vs. 46.2%; Group B: 44.5% vs. 13.2%). Those who developed grade ≥3 AEs in first‐line ICIs cohort had a more favorable survival (PFS: 8.3 vs. 3.2 months; OS: not reached vs. 5.1 months). Conclusions Our study suggested that female ES‐SCLC patients treated with immunotherapy tended to achieve a relatively longer survival. The incidence of AEs (grade ≥3) was higher in women patients receiving ICIs, which requires monitoring more closely.

oncology,respiratory system